Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763805 | 1.00 | MGLL (0.33) | MGLLCTNNB1HPGDKDM4EALDH1A1 | |
| SCHEMBL6769887 | 1.00 | MGLL (0.33) | MGLLCTNNB1HPGDKDM4EALDH1A1 | |
| SCHEMBL16378821 | 0.87 | KMT2A (0.35) | MGLLCTNNB1HPGDKDM4EALDH1A1 | |
| SCHEMBL30915237 | 0.83 | LMNA (0.34) | MGLLCTNNB1MEN1KMT2ANPC1 | |
| SCHEMBL3364797 | 0.83 | LMNA (0.34) | MGLLCTNNB1MEN1KMT2ANPC1 | |
| SCHEMBL30915236 | 0.83 | LMNA (0.34) | MGLLCTNNB1MEN1KMT2ANPC1 | |
| SCHEMBL6763775 | 0.83 | LMNA (0.34) | MGLLCTNNB1MEN1KMT2ANPC1 | |
| SCHEMBL1457093 | 0.83 | LMNA (0.34) | MGLLCTNNB1MEN1KMT2ANPC1 | |
| SCHEMBL7680321 | 0.80 | — | — | |
| SCHEMBL7680327 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730799-B2 | O-HYDROXYETHYL-O'-METHYL-BENZOFURANDIONE DIOXIMES ARE REARRANGED IN THE PRESENCE OF A DILUENT AND IN THE PRESENCE OF AN ACID OR A BASE | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-04 | — | — | US | disclosed |
| US-20020169316-A1 | Process for preparing 3-(1-hydroxyphenyl-1-alkoximinomethyl) dioxazines | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-14 | — | — | US | disclosed |
| US-6479675-B1 | Processes for preparing 3-(1-hydroxyphenyl-1-alkoximinomethyl) dioxazines | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-12 | — | — | US | disclosed |
| CN-1074765-C | Processes for preparing 3-(1-hydroxyphenyl-1-alkoximinomethyl) dioxazines | BAYER AG (DE) | 2001-11-14 | — | — | CN | disclosed |
| US-6150521-A | Process for preparing 3-(1-hydroxyphenyl-1-alkoximinomethyl) dioxazines | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-21 | — | — | US | disclosed |
| CN-1220665-A | Process for preparing 3- (1-hydroxyphenyl-1-alkoxyiminomethyl) dioxazines | BAYER AG (DE) | 1999-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169316-A1 | Process for preparing 3-(1-hydroxyphenyl-1-alkoximinomethyl) dioxazines | CYP4Z1, CYP4X1, CYP51A1 | MGLL 3831/4885CTNNB1 1365/4885HPGD 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.